Diabetic Foot Ulcer Treatment Market

Global Diabetic Foot Ulcer Treatment Market Size (2023 To 2028)

The global market size for diabetic foot ulcer treatment was worth USD 1.56 billion in 2021. This value is further estimated to be growing at a CAGR of 12.33% from 2023 to 2028 and worth USD 3.13 billion by 2028 from USD 1.75 billion in 2023.

Diabetes foot ulcers are a common complication in diabetic patients, and they can lead to leg amputation. Patients with diabetes who rely on insulin for treatment are more likely to develop a foot ulcer. In addition, patients with diabetes-related kidney, ocular, or cardiac problems and those who are overweight can develop diabetic foot ulcers. Foot ulcers are characterized by exceptional swelling, redness, irritation, and smell on one or both feet. Controlling blood sugar, removing dead tissue, wound dressings, and negative pressure therapy are all common DFU therapies. Although it is pricey, hyperbaric oxygen therapy may be useful, and surgery may improve results in some circumstances.

MARKET DRIVERS:

The growing prevalence of diabetes and the constantly growing elderly population worldwide are propelling the global diabetic foot ulcer treatment market.

Diabetic foot ulcers are one of the most common consequences of diabetes mellitus, and they are a common feature of diabetic feet. Furthermore, diabetes and its associated risk factors are on the rise at an alarming rate, which is projected to drive the worldwide diabetic foot ulcer treatment market growth over the forecast period. For instance, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014 according to WHO stats. The Prevalence has been rising more rapidly in low- and middle-income countries than in high-income countries. 

Continued prioritization to avoid surgeries and amputations is likely to drive the worldwide diabetic foot ulcer treatment market over the forecast period.

Novel therapies enhanced biologics and increased prioritization to prevent surgeries and amputations are expected to have market growth. As a result, the market is estimated to have a lot of revenue-generating opportunities during the forecast period. Novel dressings can provide moisture balance, extended oxygen permeability, antibacterial activity, growth factor stimulation, and the ability to promote autolytic debridement, so enabling the re-epithelialization process. This factor is causing the worldwide diabetic foot ulcer treatment market to grow rapidly. Chronic wounds take longer to heal and necessitate advanced wound care treatments. 

Due to an increase in the incidence of both type I and maturity-onset diabetes in industrialized economies worldwide, diabetic ulcers are becoming more widespread. As a result, the diabetic foot ulcer treatment market is predicted to grow during the forecast period as the Prevalence of diabetic foot ulcers rises. For instance, according to the stats from NCBI, The annual incidence of diabetic foot ulcers worldwide is between 9.1 to 26.1 million. Around 15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer during their lifetime.

The development of new treatment procedures and research and development activities are expected to support the rise of the market. For example, A scaffold is a new bandage treatment developed by Queen's University Belfast researchers to treat diabetic foot ulcers that is both affordable and effective for patients. The scaffolds, which are created by 3D bioprinting, gradually release antibiotics over a four-week period to treat the wound.

MARKET RESTRAINTS:

However, the high cost of ulcer treatment has kept the market from reaching its full potential. In addition, many emerging and underdeveloped countries suffer from a lack of healthcare infrastructure, which restricts the expansion of the global diabetic foot ulcer treatment market. Lack of understanding about certain treatment choices, particularly in emerging markets, is also projected to challenge market expansion.

Impact of COVID-19 on the global diabetic foot ulcer treatment market:

Since its outbreak in December 2019, the COVID-19 virus has spread to over 100 countries, prompting the World Health Organization to declare it a public health emergency. Due to the COVID-19 pandemic, competitors in the worldwide diabetic foot ulcer treatment market are experiencing substantial challenges on multiple fronts. The supply of raw materials required for producing medication formulations is a major challenge due to transportation irregularities. Furthermore, due to a surge in the number of patients suffering from COVID-19 and other life-threatening conditions, distributors are seeing irregular demand for products from retailers. As of the above factors, the market has had negative growth during the COVID-19 pandemic.

REPORT COVERAGE:

This research report on the global diabetic foot ulcer treatment market has been segmented and sub-segmented based on product, ulcer type, end-user & region.

Diabetic Foot Ulcer Treatment Market – By Product Type:

• Advanced Wound Dressings
• Skin Substitutes
• Negative Pressure Wound Therapy Devices
• Growth Factors

In 2022, the advanced wound dressings segment had the majority share in the global diabetic foot ulcer treatment market. Alginate dressings, Hydro fiber dressings, Foam dressings, Film dressings, Hydrocolloid dressings, Surgical dressings, and Hydrogel dressings are all types of wound care dressings. Nowadays, foam dressings are at the forefront of several types of wound care dressings.

However, the negative pressure wound therapy devices segment is expected to show growth during the forecast period due to the fact that it is a fast wound treatment procedure. Negative pressure therapy rapidly shrinks the wound and minimizes the swelling around the incision. Additionally, various advances in negative wound therapy like the invention of portable devices are supporting the advancement of the segment. 

Diabetic Foot Ulcer Treatment Market – By Ulcer Type:

• Neuropathic Ulcers
• Ischemic Ulcers
• Neuro-Ischemic Ulcers

In 2022, the neuro-ischemic ulcers segment held the greatest percentage of the market share. They are expected to expand at the quickest rate over the forecast period, followed by neuropathic ulcers. Neuro-ischemic ulcers are the most common among the three forms of ulcers, followed by neuropathic and ischemic ulcers.

The neuropathic ulcers segment is also expected to show significant growth during the forecast period due to the fact that several neurological conditions can result in neuropathic ulcers needing immediate treatment. In addition, neuropathic ulcers don't cause much pain due to the lack of sensation in the area affected by the patient. Therefore, it is essential to detect the problem quickly and treat it accordingly. 

Diabetic Foot Ulcer Treatment Market – By End User:

• Hospitals
• Specialty Clinics
• Long-Term Care Centers
• Ambulatory Surgical Centers

The hospital segment is projected to lead the market in terms of the end-user during the forecast period. Demand for urgent care for the treatment of chronic wounds, as well as an increase in the frequency of diabetic foot ulcers and pressure ulcers around the world, are driving the segment's expansion. However, due to a lack of hospital inpatient beds and limited resources, community health centers, and home healthcare facilities have sprung up to provide wound care. During the forecast period, this is likely to drive the community health centers and home healthcare segments.

In recent times, ambulatory care services have been on the rise due to the increasing preference for less expensive treatment alternatives. Ambulatory services are also immediate relief services and are fast and efficient at their job, further promoting segment development. 

Diabetic Foot Ulcer Treatment Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, North America dominated the global diabetic ulcer treatment market in 2022. The growing number of diabetic patients in the region and suitable healthcare facilities are driving the regional market forward. Because of North America's capital-intensive nature, long R&D and approval cycles are necessary, which acts as a stumbling block for the region's market growth. However, the dominance of North America is being aided by the increased adoption of innovative biologics and wound care devices for the treatment of these ulcers. Six US academic institutes formed the first-ever multicentre network to study diabetic foot ulcers in the United States. The National Institutes of Health is funding this program. Such advancements are expected to spark treatment development and discoveries, resulting in a positive environment for the diabetic foot ulcer treatment market in the United States over the forecast period.

Because of the increased acceptance of modern treatment alternatives in countries such as the United Kingdom, France, and Germany, Europe placed second in accounting majority of the share in the global diabetic foot ulcer treatment market.

During the forecast period, APAC is predicted to have the greatest CAGR. The regional market is growing due to rising diabetes prevalence and a high geriatric population base in India and China. In addition, increased adoption and favorable legislation in industrialized economies such as Japan and Australia can also be attributed.

KEY MARKET PARTICIPANTS:

Integra LifeSciences Corporation, Smith & Nephew, Tissue Regenix, Coloplast Corp, B. Braun Melsungen AG, 3M, Cardinal Health, ConvaTec Group Plc, and Mölnlycke Health Care AB are a few of the prominent companies operating in the global diabetic foot ulcer treatment market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• In January 2022, post receiving regulatory approval, Alkem Laboratories Ltd. (Alkem) announced plans to introduce a novel, patented technology for the treatment of diabetic foot ulcers (DFU) in India by the second half of 2022. With the help of this cutting-edge DFU management technique, many diabetic patients' amputations could be avoided. Indian patients will get access to this technology at reasonable prices at a time when there is no local treatment for DFU.
• In October 2022, Theruptor Novo, a new line of wound dressings from Healthium Medtech, was introduced on Monday for the treatment of chronic wounds such as leg ulcers and diabetic foot ulcers. Theruptor Novo, according to the MedTech business, complements Healthium's already-strong portfolio of patented solutions in the advanced wound dressing market.
• In September 2020, EpiCord Expandable, the newest development in its line of products, has been introduced by MiMedx Group, Inc., a leader in advanced wound care and a developing therapeutic biologics company. EpiCord, the device at its heart, has proven clinically effective in treating diabetic foot ulcers. These patients' care is intended to cure the wound, save their limbs, and enhance their quality of life.
• In January 2020, the launching of ConvaMaxTM, a NEW superabsorber dressing distributed by Convatec, was announced on January 2020, by Convatec Group Plc, a prominent global medical technology business. The global superabsorber market is now worth more than $100 million and is expanding at a +7% rate. For the treatment of highly exuding wounds, such as leg ulcers, pressure ulcers, diabetic foot ulcers, and dehisced surgical wounds, ConvaMaxTM superabsorber wound dressing is used.
• Orpyx Medical Technologies Inc. announced Orpyx SI Sensory Insoles with remote patient monitoring in December 2019. This is primarily used to prevent ulcers caused by neuropathy and diabetic foot ulcers.